Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews
ÁD Farias, L Eberle, TA Amador… - Advances in …, 2020 - SciELO Brasil
Background: Duloxetine and amitriptyline are antidepressants used in the treatment of
fibromyalgia. In published systematic reviews, there is no agreement about which drug is …
fibromyalgia. In published systematic reviews, there is no agreement about which drug is …
Duloxetine use in chronic painful conditions–individual patient data responder analysis
RA Moore, N Cai, V Skljarevski… - European Journal of …, 2014 - Wiley Online Library
Background Duloxetine has been studied in four distinct chronic pain conditions–
osteoarthritis (OA), fibromyalgia, chronic low back pain (CLBP) and diabetic peripheral …
osteoarthritis (OA), fibromyalgia, chronic low back pain (CLBP) and diabetic peripheral …
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder
SK Brannan, CH Mallinckrodt, EB Brown… - Journal of psychiatric …, 2005 - Elsevier
Background: While emotional symptoms such as depressed mood and loss of interest have
traditionally been considered to constitute the core symptoms of major depressive disorder …
traditionally been considered to constitute the core symptoms of major depressive disorder …
Comparison of amitriptyline and us food and drug administration–approved treatments for fibromyalgia: a systematic review and network meta-analysis
HM Farag, I Yunusa, H Goswami, I Sultan… - JAMA network …, 2022 - jamanetwork.com
Importance Amitriptyline is an established medication used off-label for the treatment of
fibromyalgia, but pregabalin, duloxetine, and milnacipran are the only pharmacological …
fibromyalgia, but pregabalin, duloxetine, and milnacipran are the only pharmacological …
A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis
TR Brown, A Slee - International journal of MS care, 2015 - meridian.allenpress.com
Background: Pain is common in multiple sclerosis (MS). Duloxetine has a potential
therapeutic role in treating MS-related pain. Methods: Thirty-eight MS patients were …
therapeutic role in treating MS-related pain. Methods: Thirty-eight MS patients were …
The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?
M Fava, CH Mallinckrodt, MJ Detke… - Journal of Clinical …, 2004 - psychiatrist.com
Background: Depression is a chronic disease consisting of emotional/psychological and
physical symptoms. Emotional symptoms have been shown to respond to currently available …
physical symptoms. Emotional symptoms have been shown to respond to currently available …
A randomized, double‐blind, placebo‐controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis
TL Vollmer, MJ Robinson, RC Risser… - Pain …, 2014 - Wiley Online Library
Background Patients with multiple sclerosis (MS) often report neuropathic pain (NP‐MS).
The purpose of this study was to assess the efficacy and tolerability of duloxetine as …
The purpose of this study was to assess the efficacy and tolerability of duloxetine as …
Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?
DGS Perahia, YL Pritchett, D Desaiah… - International clinical …, 2006 - journals.lww.com
The evidence that the effects of the antidepressant duloxetine on painful physical symptoms
in depression and chronic pain disorders are a direct analgesic effect rather than an indirect …
in depression and chronic pain disorders are a direct analgesic effect rather than an indirect …
What makes patients with fibromyalgia feel better? Correlations between Patient Global Impression of Improvement and changes in clinical symptoms and function: a …
JI Hudson, LM Arnold, LA Bradley, EHS Choy… - The journal of …, 2009 - jrheum.org
Objective. To investigate the relationship between changes in clinical rating scale items and
endpoint Patient Global Impression of Improvement (PGI-I). Methods. Data were pooled from …
endpoint Patient Global Impression of Improvement (PGI-I). Methods. Data were pooled from …
Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial
MJ Detke, Y Lu, DJ Goldstein, JR Hayes… - Journal of Clinical …, 2002 - psychiatrist.com
Background: Despite treatment advances, major depressive disorder (MDD) is still a
significant cause of morbidity and mortality. Current therapies frequently fall short of …
significant cause of morbidity and mortality. Current therapies frequently fall short of …